COVID-19 Update: See the latest on our visitor policy here. Learn More
A Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination with the Anti-Programmed Cell Death 1 (PD-1) Monoclonal Antibody Pembrolizumab (PEMBRO; Keytruda®) in Patients with Small Cell Neuroendocrine Prostate Cancer (SCNC; NEPC)
An open-label, multicenter, Phase 1b/2 study to determine the composite response rate of BXCL701 administered orally and daily, combined wit PEMBRO, in patients with Small Cell Neuroendocrine Prostate Cancer(SCNC). This study will also assess other efficacy parameters as well as the safety of the combined treatment. This study will consist of two (2) stages. Lead-in Stage, in which the safety and tolerability of the combination will be assessed and confirmed. And the Efficacy Stage, in which patients with SCNC will be treated with BXCL701 combined with PEMBRO.
Primary objectives of the study are: - To estimate the composite response rate of the combination of BXCL701 + PEMBRO in patients with SCNC. Composite response rate is defined as achieving 1 or more of the following: o Objective response by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria o Circulating tumor cell (CTC) conversion from >5/7.5 mL to <5/7.5 mL per Veridex assay by completion of Week 12 of protocol therapy o Greater than 50% prostate-specific antigen (PSA) decline from baseline by completion of Week 12 of protocol therapy Secondary Objectives The secondary objectives of the study include: - To estimate the median radiographic progression-free survival (rPFS) of the combination of BXCL701 and PEMBRO in patients with SCNC. - To estimate the median PSA progression-free survival (PSA PFS) of the combination of BXCL701 and PEMBRO in patients with SCNC. - To estimate the median overall survival (OS) of the combination of BXCL701 and PEMBRO in patients with SCNC. - To estimate the median duration of response (DOR) of the combination of BXCL701 and PEMBRO in patients with SCNC. To continue to characterize the safety profile of BXCL701 in combination with PEMBRO. - To assess population pharmacokinetics of BXCL701 using sparse pharmacokinetic sampling. - To assess the pharmacodynamic profile of the combination of BXCL701 and PEMBRO by measuring relevant effects on those cytokines previously shown to be modulated by BXCL701 in humans. Exploratory Objectives - To determine the response rate by Immune Response Evaluation Criteria In Solid Tumors (iRECIST) criteria with BXCL701 in combination with PEMBRO. - To evaluate the quantitative and qualitative effects of BXCL701 in combination with PEMBRO on relevant immune effector cytokines and various immunological effector cells, including neutrophils, myeloid derived suppressor cells (MDSCs), dendritic cells, cancer associated fibroblast (CAF) and T-cells in blood and, whenever feasible, in tumor tissues. - To explore the predictive value of baseline programmed death-ligand 1 (PD-L1) tumor expression in metastatic tumor tissue and CTCs with subsequent clinical outcomes - To explore the relationship between baseline and on-treatment circulating tumor neoantigens and T-cell repertoire and clinical outcomes (Central Laboratory) - To explore the relationship between baseline tumor messenger ribonucleic acid (mRNA) immune profiling panel and clinical outcomes.
BXCL701 (); Pembrolizumab (Keytruda)
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.